Biomedical Engineering Reference
In-Depth Information
(a)
1 h
4 h
24 h
High
T
T
Low
T
B
B
B
(b)
(c)
25
2.0
20
1.5
15
1.0
10
0.5
5
0.0
1 h
4 h
Tumor
24 h
1 h4 h
Muscle
24 h
1 h
4 h
24 h
figuRe 7.4
(a) peT/CT images of the 30 nm
64
Cu-DOTA-peg-AuNCs in a mouse bearing
an emT-6 tumor at 1, 4, and 24 h postinjection (3.7 mbq injection/mouse). b, bladder; T, tumor.
(b) SUVs in tumor and muscle regions obtained from peT/CT images taken at different times.
(c) Tumor-to-muscle SUV ratios obtained from peT/CT images taken at different time points.
(Reprinted with permission from Ref. [140]. © American Chemical Society.)
tract after oral administration and were not absorbed from a subcutaneous deposit.
With intravenous injections, a fast ReS clearance profile was confirmed. These silica
nanoparticles exhibited excellent
in vivo
stability, low cytotoxicity, and nonimmuno-
genic profiles, indicating the potential for oral drug delivery [142]. In a theranostic
application, cyclic arginine-glycine-aspartic acid with a tyrosine group (cRgDY) was
conjugated to silica nanoparticles to achieve high
in vitro
binding affinity (IC
50
= 1.2 nm)
to melanoma cells. In an animal melanoma model, targeted
124
I-cRgDY-peg-dots
Search WWH ::
Custom Search